Immuron Ltd
IMRN Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$0.88
KIRA · Stoqly’s AI analyst, in plain words
- Immuron Ltd had only $5.2M of revenue in fiscal 2026: it is still developing what it sells. It spent $1.3M on research and development, 17% of its operating costs.
- Its operating margin was −49.9%, up 23.4 pts: of every 100 in sales, about −50 is left after running the business.
- Immuron Ltd lost $2.5M in fiscal 2026. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$2.2M in fiscal 2026, −42.3% of revenue. At that burn of $2.2M a year, its $6.2M of cash and short-term investments would last about 2.8 years.
Market cap
$6.5M
P/E
—
Revenue
$5.2M
Net income
−$2.5M
Free cash flow
−$2.2M
Operating margin
−49.9%
Immuron Ltd in 30 seconds · fiscal 2026
Are shareholders being diluted?
+28.6%
A lot. The share count rose 28.6% last year, so each share owns noticeably less.
Does it make a profit?
$1.3M R&D
Not yet: it has no meaningful sales. It spent $1.3M on research and development, 17% of its operating costs.
How long would its cash last?
2.8 yrs
Comfortably. It burns $2.2M a year and holds $6.2M, about 2.8 years at that pace.
How healthy are the accounts?
3 / 8
It passes 3 of 8 health tests, but most of them need sales, so the score says little before revenue starts.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immuron Ltd does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 20-F · Sep 24, 2026
- Legal name
- Immuron Ltd
- CIK
- 0001660046
Immuron Ltd · IMRN · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.6M | $1.2M | $3.2M | $4.7M | $5.2M |
| Revenue growth | 410.3% | 118.6% | 164.8% | 46.8% | 10.8% |
| Gross margin | 68.4% | 72.5% | 68.1% | 65.4% | 64.5% |
| Operating margin | −375.0% | −197.8% | −118.3% | −73.3% | −49.9% |
| Net income | −$2.1M | −$2.5M | −$4.5M | −$3.4M | −$2.5M |
| Net margin | −373.0% | −209.8% | −141.5% | −71.6% | −47.7% |
| Diluted EPS | −$36.28 | −$44.66 | −$79.71 | −$58.51 | −$33.61 |
| Cash | |||||
| Cash from operations | −$2.3M | −$1.7M | −$3.9M | −$4.0M | −$2.2M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | — | $0.0M |
| Free cash flow | −$2.3M | −$1.8M | −$3.9M | — | −$2.2M |
| FCF margin | −412.7% | −144.2% | −119.9% | — | −42.3% |
| Share count change | — | 0.1% | 0.0% | 1.4% | 28.6% |
| Debt and strength | |||||
| Cash and short-term investments | $15.2M | $11.4M | $7.8M | $1.8M | $6.2M |
| Shareholders' equity | $15.9M | $13.0M | $8.5M | $5.3M | $7.7M |
| Current ratio | 15.8x | 9.2x | 5.5x | 5.1x | 7.3x |
| Interest coverage | −462.7x | −369.2x | −760.5x | −736.0x | −261.0x |
| Returns and quality | |||||
| Return on equity | −11.7% | −17.6% | −42.4% | −49.2% | −38.5% |
| Return on tangible equity | −13.0% | −19.6% | −53.7% | −64.1% | −32.4% |
| Piotroski F-score | 3 | 3 | 2 | 1 | 3 |
| Altman Z'' | 10.6 | 2.3 | −9.3 | −20.7 | −11.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immuron Ltd · IMRN · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.88 a share, the company is worth $6.5M.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001660046). Latest version: stoqly.net/companies/imrn. Data updated November 1, 2026. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.